Zhu’s group further confirmed that sophocarpine may be a potential drug for treating rheumatoid arthritis, demonstrating its ability to suppress the expression of proinflammatory cytokines and downregulate the MAPK and NF-κB signaling pathways (Zhu and Zhu, 2017). The gene discussed is NFKB1; the disease is rheumatoid arthritis.